柬埔寨恶性疟双氢青蒿素-哌喹治疗失败的遗传标记:基因型-表型关联研究
该研究对柬埔寨297株恶性疟原虫分离株进行全基因组关联分析,发现染色体13上的exo-E415G SNP和染色体14上plasmepsin 2-3基因扩增与哌喹体外IC50升高及双氢青蒿素-哌喹治疗失败显著相关,可作为监测哌喹耐药的分子标记。
要点
- exo-E415G SNP和plasmepsin 2-3扩增是哌喹耐药和双氢青蒿素-哌喹治疗失败的分子标记。
- 2011至2013年柬埔寨三省的哌喹体外IC50显著上升。
- 这些标记可用于监测耐药表型向大湄公河次区域其他国家的传播。
核心结论
- exo-E415G SNP和plasmepsin 2-3扩增是柬埔寨哌喹耐药和双氢青蒿素-哌喹治疗失败的标记,有助于监测这些表型向大湄公河次区域其他国家的传播并阐明哌喹耐药机制。
研究设计与样本
- 研究对来自柬埔寨的297株恶性疟原虫分离株进行全基因组关联分析,检测11 630个外显子单核苷酸多态性(SNP)和43个拷贝数变异(CNV)与体外哌喹50%抑制浓度(IC50)的关系。
- 对133例患者进行生存分析,评估候选分子标记是否预测双氢青蒿素-哌喹治疗后原虫复燃。
主要发现
- 全基因组SNP分析识别出染色体13区域与哌喹IC50升高相关,该区域内一个编码核酸外切酶基因的非同义SNP(Glu415Gly替换)与双氢青蒿素-哌喹治疗后原虫复燃相关。
- 全基因组CNV分析显示染色体5上mdr1基因单拷贝和染色体14上plasmepsin 2和plasmepsin 3基因的新扩增与哌喹IC50升高相关。
临床怎么用
- exo-E415G SNP和plasmepsin 2-3扩增可作为分子标记,用于监测柬埔寨及大湄公河次区域其他国家的哌喹耐药和双氢青蒿素-哌喹治疗失败。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As the prevalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater Mekong subregion, emerging resistance to partner drugs in artemisinin combination therapies seriously threatens global efforts to treat and eliminate this disease. Molecular markers that predict failure of artemisinin combination therapy are urgently needed to monitor the spread of partner drug resistance, and to recommend alternative treatments in southeast Asia and beyond. METHODS: We did a genome-wide association study of 297 P falciparum isolates from Cambodia to investigate the relationship of 11 630 exonic single-nucleotide polymorphisms (SNPs) and 43 copy number variations (CNVs) with in-vitro piperaquine 50% inhibitory concentrations (IC50s), and tested whether these genetic variants are markers of treatment failure with dihydroartemisinin-piperaquine. We then did a survival analysis of 133 patients to determine whether candidate molecular markers predicted parasite recrudescence following dihydroartemisinin-piperaquine treatment. FINDINGS: Piperaquine IC50s increased significantly from 2011 to 2013 in three Cambodian provinces (2011 vs 2013 median IC50s: 20·0 nmol/L [IQR 13·7-29·0] vs 39·2 nmol/L [32·8-48·1] for Ratanakiri, 19·3 nmol/L [15·1-26·2] vs 66·2 nmol/L [49·9-83·0] for Preah Vihear, and 19·6 nmol/L [11·9-33·9] vs 81·1 nmol/L [61·3-113·1] for Pursat; all p≤10-3; Kruskal-Wallis test). Genome-wide analysis of SNPs identified a chromosome 13 region that associates with raised piperaquine IC50s. A non-synonymous SNP (encoding a Glu415Gly substitution) in this region, within a gene encoding an exonuclease, associates with parasite recrudescence following dihydroartemisinin-piperaquine treatment. Genome-wide analysis of CNVs revealed that a single copy of the mdr1 gene on chromosome 5 and a novel amplification of the plasmepsin 2 and plasmepsin 3 genes on chromosome 14 also associate with raised piperaquine IC50s. After adjusting for covariates, both exo-E415G and plasmepsin 2-3 markers significantly associate (p=3·0 × 10-8 and p=1·7 × 10-7, respectively) with decreased treatment efficacy (survival rates 0·38 [95% CI 0·25-0·51] and 0·41 [0·28-0·53], respectively). INTERPRETATION: The exo-E415G SNP and plasmepsin 2-3 amplification are markers of piperaquine resistance and dihydroartemisinin-piperaquine failures in Cambodia, and can help monitor the spread of these phenotypes into other countries of the Greater Mekong subregion, and elucidate the mechanism of piperaquine resistance. Since plasmepsins are involved in the parasite's haemoglobin-to-haemozoin conversion pathway, targeted by related antimalarials, plasmepsin 2-3 amplification probably mediates piperaquine resistance. FUNDING: Intramural Research Program of the US National Institute of Allergy and Infectious Diseases, National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, Medical Research Council, and UK Department for International Development.
引用
- Amato R, Lim P, Miotto O, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2016. PMID: 27818095. doi:10.1016/S1473-3099(16)30409-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。